WO2001044282A2 - Bcl-g polypeptides, encoding nucleic acids and methods of use - Google Patents

Bcl-g polypeptides, encoding nucleic acids and methods of use Download PDF

Info

Publication number
WO2001044282A2
WO2001044282A2 PCT/US2000/033793 US0033793W WO0144282A2 WO 2001044282 A2 WO2001044282 A2 WO 2001044282A2 US 0033793 W US0033793 W US 0033793W WO 0144282 A2 WO0144282 A2 WO 0144282A2
Authority
WO
WIPO (PCT)
Prior art keywords
bcl
nucleic acid
polypeptide
seq
cell
Prior art date
Application number
PCT/US2000/033793
Other languages
English (en)
French (fr)
Other versions
WO2001044282A3 (en
Inventor
John C. Reed
Adam Godzik
Original Assignee
The Burnham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Burnham Institute filed Critical The Burnham Institute
Priority to AU25784/01A priority Critical patent/AU2578401A/en
Priority to JP2001544771A priority patent/JP2003516744A/ja
Priority to EP00989249A priority patent/EP1238080A2/en
Priority to CA002390662A priority patent/CA2390662A1/en
Publication of WO2001044282A2 publication Critical patent/WO2001044282A2/en
Publication of WO2001044282A3 publication Critical patent/WO2001044282A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Definitions

  • Bcl-G is also contemplated herein as having the ability to function as an ion channel. Additionally, Bcl-G is contemplated herein as having the ability to function target to mitochondria, for example, for example, by 'binding directly to mitochondria or via binding to a protein that is associated with mitochondria such as Bcl-2 or Bcl-X L . Bcl-G can also function to bind adenine nucleotide transporter (ANT) and to other proteins such as voltage-dependent anion channel (VDAC) . Because Bcl-G is located on chromosome 12 in a region that is frequently deleted in cancer cells (Example II) it is contemplated herein that Bcl-G functions as a tumor suppressor.
  • ANT adenine nucleotide transporter
  • VDAC voltage-dependent anion channel
  • Bcl-2 family proteins are central regulators of apoptosis (reviewed in Reed, J. C, Nature, 387:773-776 (1997); Adams & Cory, Science, 281:1322-1326 (1998);
  • the invention additionally provides a nucleic acid that hybridizes under high stringency conditions to the Bcl-G coding portion of any of SEQ ID NOS:l, 3 or 41.
  • the invention also provides a nucleic acid having a nucleotide sequence the same or substantially the same as set that forth in any of SEQ ID NOS:l, 3 or 41.
  • optionally labeled Bcl-G-encoding nucleic acids, or fragments thereof can be employed to probe a library, for example, a cDNA or genomic library, and the like for additional nucleic acid sequences encoding novel Bcl-G polypeptides. Construction of suitable cDNA libraries is well-known in the art.
  • a Bcl-G nucleic acid molecule specifically excludes nucleic acid molecules consisting of any of the nucleotide sequences having the Genbank (gb) , EMBL (emb) or DDBJ (dbj) accession numbers described below.
  • a Bcl-G polypeptide fragment specifically excludes the amino acid fragments encoded by the nucleotide sequences having the GenBank accession numbers described below.
  • GenBank accession numbers specifically excluded include AC005903, AC007439, AW000827, AA399486, AW001213, AI478889, AA400686, AA398276, AI240211, and AA536718.
  • GenBank accession numbers specifically excluded include AC005903, AC007439, AW000827, AA399486, AW001213, AI478889, AA400686, AA398276, AI240211, and AA536718.
  • the invention thus provides methods for detecting Bcl-G nucleic acid in a sample.
  • the methods of detecting Bcl-G nucleic acid in a sample can be either qualitative or quantitative, as desired. For example, the presence, abundance, integrity or structure of a Bcl- G can be determined, as desired, depending on the assay format and the probe used for hybridization or primer pair chosen for application.
  • the Bid protein contains a N-terminal domain of -56 amino-acids that masks its BH3 domain, reducing its ability to dimerize with other Bcl-2 family proteins.
  • the N-terminal domain exposes the BH3 domain and is associated with translocation of Bid from the cytosol to mitochondria, where it induces cytochrome c release and apoptosis (Li et al., Cell, 94:491-501 (1998); Luo et al., Cell, 94:481-490 (1998)).
  • the amino acid length of functional fragments or polypeptide anlogs of the present invention can range from about 5 amino acids up to the full-length protein sequence of an invention Bcl-G.
  • the amino acid lengths include, for example, at least about 10 amino acids, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 75, at least about 100, at least about 150, at least about 200, at least about 250 or more amino acids in length up to the full-length Bcl-G protein sequence.
  • the functional fragments can be contiguous amino acid sequences of a Bcl-G polypeptide, including contiguous amino acid sequences of SEQ ID NOS: 2, 4 or 42.
  • Bcl-G polypeptides or a functional portion thereof, can be directly administered to an individual.
  • Methods of administering therapeutic polypeptides are well known to those skilled in the art, for example, as a pharmaceutical composition.
  • a Bcl-G polypeptide, or functional fragment thereof can be administered to an individual so that the Bcl-G polypeptide or functional fragment is targeted to a tumor to induce apoptosis or otherwise function as a tumor suppressor.
  • One method of delivering a Bcl-G polypeptide to an intracellular target is to fuse a Bcl-G polypeptide or functional fragment to an intracellular-targeting peptide that can penetrate the cell membrane or otherwise deliver a polypeptide to the intracellular environment such as via internalization, thereby causing the fused Bcl-G polypeptide to enter the cell.
  • Vectors useful for expression in eukaryotic cells can include, for example, regulatory elements including the SV40 early promoter, the cytomegalovirus (CMV) promoter, the mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, and the like.
  • CMV cytomegalovirus
  • MMTV mouse mammary tumor virus
  • MMLV Moloney murine leukemia virus
  • An anti-Bcl-G antibody, or antigen binding fragment of such an antibody is characterized by having specific binding activity for a Bcl-G polypeptide or a peptide portion thereof of at least about 1 x 10 5 M "1 .
  • Fab, F(ab') 2 , Fd and Fv fragments of an anti-Bcl-G antibody, which retain specific binding activity for a Bcl-G polypeptide are included within the definition of an antibody.
  • antibody as used herein includes naturally occurring antibodies as well as non-naturally occurring antibodies, including, for example, single chain antibodies, chimeric, bifunctional and humanized antibodies, as well as antigen-binding fragments thereof.
  • non-naturally occurring antibodies can be constructed using solid phase peptide synthesis, can be produced recombinantly or can be obtained, for example, by screening combinatorial libraries consisting of variable heavy chains and variable light chains as described by Huse et al .
  • the labeling means can be a fluorescent labeling agent that chemically binds to antibodies or antigens without denaturation to form a fluorochrome (dye) that is a useful immunofluorescent tracer.
  • a fluorochrome a fluorochrome that is a useful immunofluorescent tracer.
  • a description of immunofluorescent analytic techniques is found in DeLuca, "Immunofluorescence Analysis", in Antibody As a Tool, Marchalonis et al . , eds., John Wiley & Sons, Ltd., pp. 189-231 (1982), which is incorporated herein by reference.
  • diagnostic systems preferably in kit form, comprising at least one invention nucleic acid or antibody in a suitable packaging material.
  • the diagnostic kits containing nucleic acids are derived from the Bcl-G-encoding nucleic acids described herein.
  • the diagnostic nucleic acids are derived from any of SEQ ID NOS:l, 3 or 41 and can be oligonucleotides of the invention.
  • Invention diagnostic systems are useful for assaying for the presence or absence of nucleic acid encoding Bcl-G in either genomic DNA or mRNA.
  • Bcl-G is located in a 600 kb region that has been previously determined to be frequently deleted in childhood ALL and other solid tumors (Baens et al . , supra , 1999) . Therefore, Bcl-G is located in a region deleted in ALL and can function as a tumor suppressor or as a marker for tumor suppressor activity.
  • Bcl-2 family proteins such as Bcl-2, Bcl-X L , and Bak, contain a hydrophobic stretch of amino- acids near their carboxyl-terminus that anchors them in intracellular membranes of mitochondria, endoplasmic reticulum, or nuclear envelope (reviewed in Reed, J. C, Nature, 387:773-776 (1997); Adams & Cory, Science, 281:1322-1326 (1998); Gross et al . , Genes Dev., 13:1899- 1911 (1999)).
  • This example describes loss of heterozygosity (LOH) associated with Bcl-G in ovarian cancer tissue.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/US2000/033793 1999-12-14 2000-12-13 Bcl-g polypeptides, encoding nucleic acids and methods of use WO2001044282A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU25784/01A AU2578401A (en) 1999-12-14 2000-12-13 Bcl-g polypeptides, encoding nucleic acids and methods of use
JP2001544771A JP2003516744A (ja) 1999-12-14 2000-12-13 Ｂｃｌ−ｇポリペプチド、それをコードする核酸および使用方法
EP00989249A EP1238080A2 (en) 1999-12-14 2000-12-13 Bcl-g polypeptides, encoding nucleic acids and methods of use
CA002390662A CA2390662A1 (en) 1999-12-14 2000-12-13 Bcl-g polypeptides, encoding nucleic acids and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46164199A 1999-12-14 1999-12-14
US09/461,641 1999-12-14

Publications (2)

Publication Number Publication Date
WO2001044282A2 true WO2001044282A2 (en) 2001-06-21
WO2001044282A3 WO2001044282A3 (en) 2002-02-21

Family

ID=23833374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033793 WO2001044282A2 (en) 1999-12-14 2000-12-13 Bcl-g polypeptides, encoding nucleic acids and methods of use

Country Status (5)

Country Link
EP (1) EP1238080A2 (ja)
JP (1) JP2003516744A (ja)
AU (1) AU2578401A (ja)
CA (1) CA2390662A1 (ja)
WO (1) WO2001044282A2 (ja)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057213A2 (en) * 2000-02-04 2001-08-09 Lexicon Genetics Incorporated Human bcl-x-like proteins and polynucleotides encoding the same
WO2005042582A1 (ja) * 2003-11-04 2005-05-12 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
WO2008023841A1 (en) * 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Breast cancer-associated gene, melk, and its interactions with bcl-g
EP1691824B1 (en) * 2003-11-19 2009-03-11 Survac ApS Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
US7687465B2 (en) 2003-04-11 2010-03-30 Kraeftens Bekaempelse Therapeutic cancer vaccine
US8030461B2 (en) 2002-04-15 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for constructing scDb libraries
US8337841B2 (en) 2003-01-21 2012-12-25 Chugai Seiyaku Kabushiki Kaisha Methods of screening for antibody light chains
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US9777066B2 (en) 2005-06-10 2017-10-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
EP1908482B1 (en) 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000642A1 (en) * 1993-06-22 1995-01-05 Arch Development Corporation Vertebrate apoptosis gene: compositions and methods
WO1995028497A1 (en) * 1994-04-13 1995-10-26 La Jolla Cancer Research Foundation Interaction of proteins involved in a cell death pathway
US5691179A (en) * 1993-08-26 1997-11-25 Washington University Cell death regulators
WO1997045128A1 (en) * 1996-05-29 1997-12-04 Apoptosis Technology, Inc. Apoptosis associated protein bbk

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000642A1 (en) * 1993-06-22 1995-01-05 Arch Development Corporation Vertebrate apoptosis gene: compositions and methods
US5691179A (en) * 1993-08-26 1997-11-25 Washington University Cell death regulators
WO1995028497A1 (en) * 1994-04-13 1995-10-26 La Jolla Cancer Research Foundation Interaction of proteins involved in a cell death pathway
WO1997045128A1 (en) * 1996-05-29 1997-12-04 Apoptosis Technology, Inc. Apoptosis associated protein bbk

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [Online] 26 April 1999 (1999-04-26) MARRA M. ET AL. : "Stratagene mouse testis (#937308) Mus musculus cDNA clone" retrieved from EBI Database accession no. AI614194 XP002174349 *
DATABASE EMBL [Online] 31 July 1997 (1997-07-31) MARRA M. ET AL.: " Knowles Solter mouse 2 cell Mus musculus cDNA clone " retrieved from EBI Database accession no. AA536718 XP002174348 *
GUO, BIN ET AL: "Bcl - G, a novel pro-apoptotic member of the Bcl-2 family" J. BIOL. CHEM. (2001), 276(4), 2780-2785 , XP002174347 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057213A3 (en) * 2000-02-04 2002-02-21 Lexicon Genetics Inc Human bcl-x-like proteins and polynucleotides encoding the same
WO2001057213A2 (en) * 2000-02-04 2001-08-09 Lexicon Genetics Incorporated Human bcl-x-like proteins and polynucleotides encoding the same
US8030461B2 (en) 2002-04-15 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for constructing scDb libraries
US8337841B2 (en) 2003-01-21 2012-12-25 Chugai Seiyaku Kabushiki Kaisha Methods of screening for antibody light chains
US7687465B2 (en) 2003-04-11 2010-03-30 Kraeftens Bekaempelse Therapeutic cancer vaccine
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
WO2005042582A1 (ja) * 2003-11-04 2005-05-12 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
EP1691824B1 (en) * 2003-11-19 2009-03-11 Survac ApS Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
US7842294B2 (en) 2003-11-19 2010-11-30 Survac Aps Proteins belonging to the Bcl-2 family and fragments thereof, and their use in cancer patients
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US11168344B2 (en) 2005-03-31 2021-11-09 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US9777066B2 (en) 2005-06-10 2017-10-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US10934344B2 (en) 2006-03-31 2021-03-02 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
WO2008023841A1 (en) * 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Breast cancer-associated gene, melk, and its interactions with bcl-g
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide

Also Published As

Publication number Publication date
EP1238080A2 (en) 2002-09-11
CA2390662A1 (en) 2001-06-21
JP2003516744A (ja) 2003-05-20
WO2001044282A3 (en) 2002-02-21
AU2578401A (en) 2001-06-25

Similar Documents

Publication Publication Date Title
US7626001B2 (en) Card domain containing polypeptides, encoding nucleic acids, and methods of use
US7834149B2 (en) Card-domain containing polypeptides, encoding nucleic acids, and methods of use
EP1238080A2 (en) Bcl-g polypeptides, encoding nucleic acids and methods of use
US7982002B2 (en) Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
US7927832B2 (en) Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
EP0988317B1 (en) Aib1, a steroid receptor co-activator
US8034901B2 (en) Bcl-G polypeptides, encoding nucleic acids and methods of use
AU2001265036A1 (en) Card domain containing polypeptides, encoding nucleic acids, and methods of use
US6638734B1 (en) Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
US7041783B2 (en) Survivin-binding proteins, encoding nucleic acids, and methods of use
EP1185652A2 (en) Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
US20050037378A1 (en) CARD3X-2 polypeptides, encoding nucleic acids, and methods of use
JP2004504002A (ja) ヒトシャペロンタンパク質

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 25784/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2390662

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 544771

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000989249

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000989249

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000989249

Country of ref document: EP